Lilly VERVE-102 single infusion durably lowered PCSK9 up to 88% and LDL-C up to 62%. Phase 1b Heart-2 results showed a single IV base-editing dose gave dose-dependent, durable PCSK9 and LDL-C reductions up to 18 months in HeFH or premature CAD patients. The treatment was well tolerated and received FDA Fast Track designation; Phase 2 is planned.
Insights / Pharma
PharmaLilly VERVE-102 single infusion durably lowers PCSK9 up to 88% and LDL-C up to 62%
Lilly VERVE-102 single infusion durably lowered PCSK9 up to 88% and LDL-C up to 62% in Phase 1b Heart-2 trial, with dose-dependent, durable reductions up to 18 months in patients with heterozygous familial hypercholesterolemia or premature coronary artery disease.
